341 related articles for article (PubMed ID: 34468898)
1. Drug repositioning for anti-tuberculosis drugs: an in silico polypharmacology approach.
Madugula SS; Nagamani S; Jamir E; Priyadarsinee L; Sastry GN
Mol Divers; 2022 Jun; 26(3):1675-1695. PubMed ID: 34468898
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
4. A QSAR and molecular modelling study towards new lead finding: polypharmacological approach to Mycobacterium tuberculosis.
Janardhan S; John L; Prasanthi M; Poroikov V; Narahari Sastry G
SAR QSAR Environ Res; 2017 Oct; 28(10):815-832. PubMed ID: 29183232
[TBL] [Abstract][Full Text] [Related]
5. Polypharmacological repurposing approach identifies approved drugs as potential inhibitors of Mycobacterium tuberculosis.
Singh J; Quadir N; Vashishtha S; Chakraborty A; Alam A; Kundu B; Ahmad U; Sundar D; Ehtesham NZ; Hasnain SE
Biochem J; 2023 Jul; 480(14):1079-1096. PubMed ID: 37306466
[TBL] [Abstract][Full Text] [Related]
6.
Jagadeb M; Rath SN; Sonawane A
J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
[TBL] [Abstract][Full Text] [Related]
7. A Repurposing Approach for Uncovering the Anti-Tubercular Activity of FDA-Approved Drugs with Potential Multi-Targeting Profiles.
Battah B; Chemi G; Butini S; Campiani G; Brogi S; Delogu G; Gemma S
Molecules; 2019 Nov; 24(23):. PubMed ID: 31795400
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and antimycobacterial evaluation of novel adamantane and adamantanol analogues effective against drug-resistant tuberculosis.
Alsayed SSR; Lun S; Payne A; Bishai WR; Gunosewoyo H
Bioorg Chem; 2021 Jan; 106():104486. PubMed ID: 33276981
[TBL] [Abstract][Full Text] [Related]
9. A multidrug efflux protein in Mycobacterium tuberculosis; tap as a potential drug target for drug repurposing.
Dwivedi M; Mukhopadhyay S; Yadav S; Dubey KD
Comput Biol Med; 2022 Jul; 146():105607. PubMed ID: 35617724
[TBL] [Abstract][Full Text] [Related]
10. [Prospects for development of new antituberculous drugs].
Tomioka H
Kekkaku; 2002 Aug; 77(8):573-84. PubMed ID: 12235850
[TBL] [Abstract][Full Text] [Related]
11. Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv.
Ramakrishnan G; Chandra NR; Srinivasan N
Mol Biosyst; 2015 Dec; 11(12):3316-31. PubMed ID: 26429199
[TBL] [Abstract][Full Text] [Related]
12. Atosiban and Rutin exhibit anti-mycobacterial activity - An integrated computational and biophysical insight toward drug repurposing strategy against Mycobacterium tuberculosis targeting its essential enzyme HemD.
Sharma R; Muthu SA; Agarwal M; Mehto NK; Pahuja I; Grover A; Dwivedi VP; Ahmad B; Grover S
Int J Biol Macromol; 2023 Dec; 253(Pt 6):127208. PubMed ID: 37816464
[TBL] [Abstract][Full Text] [Related]
13. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
Adeniji AA; Knoll KE; Loots DT
Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
[TBL] [Abstract][Full Text] [Related]
14. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
15. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
16. Repurposed drug candidates for antituberculosis therapy.
An Q; Li C; Chen Y; Deng Y; Yang T; Luo Y
Eur J Med Chem; 2020 Apr; 192():112175. PubMed ID: 32126450
[TBL] [Abstract][Full Text] [Related]
17. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
18. Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis.
Stelitano G; Sammartino JC; Chiarelli LR
Molecules; 2020 Mar; 25(5):. PubMed ID: 32182964
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel multitarget antitubercular inhibitors against mycobacterial peptidoglycan biosynthetic Mur enzymes by structure-based virtual screening.
Kumari M; Subbarao N
J Biomol Struct Dyn; 2022 Nov; 40(18):8185-8196. PubMed ID: 33826470
[TBL] [Abstract][Full Text] [Related]
20. In silico Screening of Food and Drug Administration-approved Compounds against Trehalose 2-sulfotransferase (Rv0295c) in Mycobacterium tuberculosis: Insights from Molecular Docking and Dynamics Simulations.
Sharma D; Gautam S; Srivastava N; Bisht D
Int J Mycobacteriol; 2024 Jan; 13(1):73-82. PubMed ID: 38771283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
